Preferred Label : crizanlizumab;
MeSH synonym : critznlizumab;
UNII : L7451S9126;
Origin ID : C000614139;
UMLS CUI : C4524703;
ATC code(s)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/informations-de-securite/adakveo-crizanlizumab-retrait-de-lautorisation-de-mise-sur-le-marche-en-raison-dun-manque-defficacite
2023
false
false
false
France
French
drug information
Drug effect lack of
crizanlizumab
crizanlizumab
anemia, sickle cell
Vaso-Occlusive Crisis
Safety-Based drug withdrawals
---
https://www.has-sante.fr/jcms/p_3264981/fr/adakveo-crizanlizumab
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
crizanlizumab
infusions, intravenous
crizanlizumab
anemia, sickle cell
Vaso-Occlusive Crisis
antibodies, monoclonal, humanized
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/adakveo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Crizanlizumab
Crizanlizumab
drug approval
europe
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
crizanlizumab
orphan drug production
pain
young adult
adult
anemia, sickle cell
drug therapy, combination
hydroxyurea
infusions, intravenous
P-Selectin
product surveillance, postmarketing
Vaso-Occlusive Crisis
aged
pregnancy
breast feeding
drug evaluation, preclinical
crizanlizumab
crizanlizumab
antibodies, monoclonal
antibodies, monoclonal
---
